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CONCLUSIONS
Pulmonary carcinoid tumors account for 1–2% 
of all invasive lung malignancies. They generally 
occur between the fourth and the sixth decade 
of life. Most pulmonary carcinoid tumors are 
well differentiated, have < 2 mitoses/10 HPF 
and < 3% Ki67 index (typical carcinoid). A small 
percentage are aggressive, have 2-20 mitoses/10 
HPF and 3-20% Ki67 index (atypical carcinoid). 
Because of their rarity, there are very few large 
studies on pulmonary carcinoid and most of 
them are retrospective in nature. We present a 
retrospective analysis of the clinico-pathologic 
features of patients diagnosed with pulmonary 
carcinoids tumor at our institution over a ten 
year period.
After approval by the institutional review board, 
we identify all patients with pulmonary carcinoid 
tumors diagnosed or treated at the Lehigh Valley 
Hospital between 2005 and 2015. We performed a 
retrospective review of the records of all biopsy-
confirmed patients with pulmonary carcinoid tumors. 
Collected data included clinical presentation, 
demographics, pathology, treatment modalities, 
pattern of metastases and recurrence. All analyses 
were conducted using SAS version 9.3. Kaplan-Meier 
method was used for overall survival calculation.
This study though retrospective in nature nevertheless add to the clinico-pathologic features known of pulmonary carcinoid tumor. It is more common in women and occur mostly in 
the 5th to 6th decades of life. While most tumors are incidental findings on imaging, the common presenting symptoms are cough, dyspnea, chest pain, pneumonia and hemoptysis. 
Surgery is the mainstay of treatment. Chemotherapy and radiation therapy are rarely used except in the metastatic setting. Keeping with the indolent nature of the disease, most 
patients that died during the study period died of causes other than pulmonary carcinoid, and disease recurrence was rare.




  Male 69%
  Female 31%
  Median age 63.5 years (IQR 52, 73)
Tumor Types
  Typical carcinoid 90%
  Atypical carcinoid 10%
Tobacco use
  Smoke(d) 44%
  Never smoked 56%
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Stage of Cancer at Time of Diagnosis 
















90% of Patients Underwent Definitive Invasive Intervention
Intervention/Extent   






Treatments of the 6 Patients with Stage IV Disease





Patient A Typical Bilateral lungs Endobronchial ablation None
Indolent disease, lived >5 years 
from diagnosis
Patient B Typical Bilateral lungs None None Indolent disease, Aliave >1 yr after diagnosis
Patient C Atypical Bone None
6 cycles of cisplatin and 
etoposide followed by 6300 
cGy RT to residual tumor in the 
Mediastinum
Alive 4 years after treatment
Patient D Typical Bone None Unknown agents followed by palliation RT to the bone Died <2 years after diagnosis
Patient E Atypical Liver, Lung, Bone, Brain None
1st line: cisplatin+etoposide. PCI
2nd: carboplatin+paclitaxel,
3rd: 1 cycle of gemcitabine GK
Died 15 months after diagnosis




None Alive 3 years after diagnosis
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Two other patients received chemotherapy: one was misdiagnosed small cell lung carcinoma and the other was s tage IIIA pulmonary 
carcinoid tumor.
Survival Results
4 patients had disease recurrence 2 of whom died during the study period.
11 of 96 patients died during the study period; 9 of them of causes other than pulmonary 
carcinoid. The two patients that died of pulmonary carcinoid both had atypical histology.
METHODS
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